Department of Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmacy, Johannes Gutenberg-University, Staudingerweg 5, Mainz 55099, Germany.
J Pharm Sci. 2010 Oct;99(10):4427-36. doi: 10.1002/jps.22148.
The goal of this study was to investigate the in vitro-in vivo correlation (IVIVC) for fenofibrate immediate release (IR) tablet formulations based on MeltDose-technique. The in vitro determined drug solubility and permeability data were related to the C(max) values observed from two in vivo human studies. Solubility and permeation studies of fenofibrate were conducted in medium simulating the fasted state conditions in the upper jejunum, containing the surfactant compositions of the six formulations at different concentrations. The behavior of all surfactant compositions was characterized by surface tension, dynamic light scattering, and cryo-TEM. The obtained solubility and permeation data were combined and compared with the C(max) values for the fenofibrate formulations, assuming a 50 mL in vivo dissolution volume. A good IVIVC was observed for five fenofibrate formulations (R(2) = 0.94). The in vitro studies revealed that the formulation compositions containing sodium lauryl sulfate (SLS) interfered with the vesicular drug solubilizing system of the biorelevant medium and antagonized its solubilization capacity. The opposing interaction of surfactants with the emulsifying physiological constituents in intestinal juice should be taken into consideration in order to prevent unsatisfactory in vivo performance of orally administered formulations with low soluble active pharmaceutical ingredients.
本研究旨在考察基于 MeltDose 技术的非诺贝特速释片剂制剂的体外-体内相关性(IVIVC)。将体外测定的药物溶解度和渗透性数据与来自两项人体体内研究的 Cmax 值相关联。在模拟上消化道空腹条件的介质中进行了非诺贝特的溶解度和渗透性研究,该介质中含有六种制剂的表面活性剂组合物,浓度不同。所有表面活性剂组合物的行为均通过表面张力、动态光散射和冷冻透射电镜进行了表征。将获得的溶解度和渗透性数据与非诺贝特制剂的 Cmax 值相结合,假设体内溶解体积为 50 mL。观察到五种非诺贝特制剂的良好 IVIVC(R2 = 0.94)。体外研究表明,含有月桂基硫酸钠(SLS)的制剂组合物干扰了生物相关介质中的囊泡药物增溶体系,并拮抗了其增溶能力。为了防止低溶解度的活性药物成分的口服制剂在体内表现不佳,应考虑表面活性剂与肠液中的乳化生理成分的相反相互作用。